TP53 and neoplasm: The activity of ceramides A (1) and B (2) was investigated in an EAC mouse model, where both ceramides at doses of 1 and 2 mg/kg significantly decreased the tumor size, serum levels of VEGF-B and TNF-α, and expression of the biomarker midkine growth factor in the tumor tissue, with significant upregulation of the apoptotic factors p53, Bax, and caspase-3.